CN105343350A - Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases - Google Patents

Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases Download PDF

Info

Publication number
CN105343350A
CN105343350A CN201510819922.XA CN201510819922A CN105343350A CN 105343350 A CN105343350 A CN 105343350A CN 201510819922 A CN201510819922 A CN 201510819922A CN 105343350 A CN105343350 A CN 105343350A
Authority
CN
China
Prior art keywords
hyperuricemia
erding granules
gout
uric acid
erding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510819922.XA
Other languages
Chinese (zh)
Inventor
杨世林
冯育林
李俊
张武岗
简辉
左洁羽
王木兰
许溪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Bencao Tiangong Technology Co Ltd
Original Assignee
Jiangxi Bencao Tiangong Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Bencao Tiangong Technology Co Ltd filed Critical Jiangxi Bencao Tiangong Technology Co Ltd
Priority to CN201510819922.XA priority Critical patent/CN105343350A/en
Publication of CN105343350A publication Critical patent/CN105343350A/en
Pending legal-status Critical Current

Links

Abstract

The invention provides an application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases. Provided evidences indicate that the Erding granules have new application of obviously preventing and treating hyperuricemia and gout diseases. The Erding granules are disclosed to have obvious hypouricemic effect, so as to reduce serum uric acid values of hyperuricemia and gout diseases and alleviate clinical symptoms of patients with gout.

Description

Erding granules is treated in preparation or is prevented the application in the medicine of hyperuricemia and gout disease
Technical field
The present invention relates to the new opplication of Erding granules, particularly relate to Erding granules and treat in preparation or prevent the application in the medicine of hyperuricemia and gout disease.
Background technology
Uric acid is the end-product of purine metabolism, and stable uric acid level relate to the balance between uricopoiesis, absorption and excretion, decomposition.Once said process gets muddled, uricopoiesis will be caused to increase or discharge minimizing, causing hyperuricemia (hyperuricemia, HUA).When crystallization deposition is in distal joint, cause simple joint or multiarticulate acute synovitis; When uric acid crystal is deposited on subcutaneous, can form tophus, can there is destruction of joint, impaired renal function in gout severe patient.The Patients with Hyperuricemia of 5% ~ 12% is about had finally to develop into gout (gout) according to statistics.In recent years, some researchs show, blood uric acid raises and is proportionate with the generation of kidney disease, atherosclerosis, essential hypertension, apoplexy, cardiovascular event and death etc., and does not rely on some common cardiovascular risk factors and injury of kidney.HUA has related to developing of multiple organ multisystem disease, as the independent hazard factor of multiple cardiovascular and cerebrovascular disease, the most important biochemical basis of gout and the most dangerous risk factor, has caused the attention of numerous medical personnels.Therefore, strengthen having important practical significance to the prevention and therapy research of hyperuricemia.Be used for the treatment of the clinical medicine of this disease at present---Western medicine, although can suppress uricopoiesis medicine, reduces generation and the synthesis of uric acid in body, has untoward reaction such as suppressing marrow function, gastrointestinal irritation and allergic drug eruption; The medicine of uricosuric excretion can promote tubular excretion uric acid, but such medicine has the side effect of sulfa drugs, often causes allergic dermatitis and gastrointestinal reaction.
Summary of the invention
The object of this invention is to provide Erding granules treat in preparation or prevent the application in the medicine of hyperuricemia and gout disease.
As the common medicine of heat-clearing and toxic substances removing---Erding granules records in " Chinese Pharmacopoeia ", is made up of Herba Violae, Herba Lobeliae Chinensis, Herba Taraxaci, Radix Isatidis four Chinese medicine material, furuncle carbuncle poison, laryngopharynx swelling and pain, wind heat acute catarrhal conjunctivitis caused by containing for burning hot poison.The side of the party separates: Herba Violae, taste bitter, acrid, cold, tool heat-clearing and toxic substances removing, and removing heat from blood is subsided a swelling, clearing away heat-damp and promoting diuresis effect; Herba Lobeliae Chinensis, tool inducing diuresis to remove edema, heat-clearing toxin-expelling functions; Herba Taraxaci, sweet, micro-hardship, cold, tool heat-clearing and toxic substances removing, dispersing swelling and dissipating binds effect; Radix Isatidis, bitter in the mouth is trembled with fear, and has effect of heat-clearing and toxic substances removing, removing heat from blood detumescence, sore-throat relieving.Show that the property of medicine of four Chinese medicine all meets the determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs to gout of the traditional Chinese medical science by the square solution of Erding granules prescription, therefore, Erding granules has the theoretical foundation of clearly treating gout.
The present invention uses Chinese Pharmacopoeia kind---and Erding granules has carried out the uric acid resisting Effect study of mice, rat, Carnis Coturnicis japonicae hyperuricemia pharmacological model, result shows that Erding granules has obvious uric acid resisting effect to the mice of hyperuricemia, rat, Carnis Coturnicis japonicae, and then show that it has therapeutical effect to hyperuricemia, simultaneously based on the primary biochemical indicator of hyperuricemia as gout disease, therefore, also there is certain gout effect.
In sum, Erding granules has the application in the medicine of preparation treatment or prevention hyperuricemia and gout disease.
Detailed description of the invention
trial drug
Erding granules extractum (according to the preparation of Chinese Pharmacopoeia preparation method); Allopurinol (Xinyi, Shanghai everything Pharmaceutical, lot number: 111102); Benzbromarone.
animal
Kunming mouse, male, 16 ~ 18g, is purchased from Shanghai Slac Experimental Animal Co., Ltd., animal credit number: SCXK(Shanghai) 2012-0002; SD rat, 180 ~ 220g, male, be purchased from Hunan Si Laike Jing Da laboratory animal company limited, animal credit number: SCXK(Hunan) 2011-0003; Korea dragon city Carnis Coturnicis japonicae, 80 ~ 110g, male, 50, prosperous Carnis Coturnicis japonicae kind field, Jiangxi; Animal adaptability is fed one week, free diet, drinking-water.
reagent
Oteracil Potassium (sigma, lot number: STBC1486V, prepares with 0.5%CMC-Na); Hypoxanthine (Suo Laibao); Yeast dry powder (Britain OXOID); (Bioengineering Research Institute is built up in Nanjing to uric acid reagent box, lot number: 20140528);
embodiment 1: Erding granules is to the experimental technique of hyperuricemia mice serum uric acid
(1) Oteracil Potassium is caused to the experimental technique of hyperuricemia (single model) mice
60 male KM mices, be divided into 6 groups at random, normal group, model group, allopurinol group, Erding granules (10,20,40g raw medicinal herbs/kg) three dosage groups, often organize 10, normal group and model group gavage normal saline, allopurinol group gavage 15mg/kg allopurinol, Erding granules three dosage component other gavage Erding granules extractum, every day is administered once, continuous 5d.1h before last administration, except normal group, all the other each treated animal lumbar injection 450mg/kg Oteracil Potassiums set up hyperuricemia model [7], normal group injects isopyknic 0.5%CMC-Na, 1h after administration, mouse orbit venous blood sampling 0.5ml, and room temperature places 1h, and with 3500r/min, centrifugal 10min, gets serum, builds up uric acid reagent box description detect serum uric acid (SUA) level according to Nanjing.
Erding granules 40g crude drug/kg energy significance reduction hyperuricemia mice serum uric acid ( p< 0.01), the results detailed in Table 1.
(2) Oteracil Potassium is caused to the experimental technique of hyperuricemia (continuous model) mice
60 male KM mices, are divided into 6 groups at random, normal group, model group, allopurinol group, Erding granules (10,20,40g raw medicinal herbs/kg) three dosage groups, often organize 10.Except normal group, all the other are respectively organized and adopt every day 250mg/kg Oteracil Potassium gavage to set up hyperuricemia model [8]normal group gavage 0.5%CMC-Na, after modeling, 1h respectively organizes gavage relative medicine, normal group and model group gavage equal-volume normal saline, continuous 6d, 1h after last administration, mouse orbit venous blood sampling 0.5ml, room temperature places 1h, centrifugal with 3500r/min, 10min, gets serum, builds up uric acid reagent box description detect serum uric acid (SUA) level according to Nanjing.
Erding granules three dosage groups all can significance reduce hyperuricemia continuous model mice serum uric acid ( p< 0.01), the results detailed in Table 2.
embodiment 2: Erding granules is to the experimental technique of hyperuricemia rat blood serum uric acid
60 rats are divided at random: normal group, model group, allopurinol and Erding granules high, medium and low (24,12,6g/kg) three dosage groups, totally 6 groups, often organize 10.Model group and normal group gavage equal-volume normal saline, the corresponding medicinal liquid of all the other administration group gavages, 1ml/100g body weight, continuous 5d.Adopt hypoxanthine 500mg/kg gavage, oxonic acid potassium salt 100mg/kg subcutaneous injection sets up hyperuricemia model, 1h after modeling, carry out last administration, positive drug (allopurinol) only at this moment between be administered once, after administration, 2h gets blood, 3500r/min, centrifugal 10min, gets serum, and full automatic biochemical apparatus detects serum uric acid (UA) value.
From table 3, model group animal serum uric acid compared with normal group significance raises (P < 0.01), shows that rat hyperuricemia model is successfully established; In administration group, Erding granules high dose and allopurinol group serum uric acid comparatively model group significance reduce (P < 0.05 or P < 0.01), and Erding granules high dose group has obvious uric acid resisting effect.
embodiment 3: Erding granules is to the experimental technique of hyperuricemia Serum of Quail uric acid
50 Carnis Coturnicis japonicaes are divided into normal group, model group at random, the large and small dosage group of Erding granules (10,5g/kg), benzbromarone group (20mg/kg), totally 5 groups, often organize 10.Except normal group feed Carnis Coturnicis japonicae normal diet, all the other each group all gives high purine feedstuff (normal diet admixes yeast dry powder 15gkg -1d -1, after food, supplement normal diet), freely drink water.Normal group and model group gavage 0.5%CMC-Na, all the other respectively organize gavage relative medicine, and 10ml/kg experimental period is 14d.In administration after 14 days, before getting blood, water 12h is can't help in fasting, taking blood from jugular vein 1ml, and after leaving standstill 1h, the centrifugal 10min of 3500r/min, gets serum, and full automatic biochemical apparatus detects uric acid.
From table 4, modeling is after 14 days, and model group animal serum uric acid compared with normal group significance raises (P < 0.05), shows that Carnis Coturnicis japonicae hyperuricemia model is successfully established; The heavy dose of group of Erding granules and positive drug benzbromarone group uric acid comparatively model group significance reduction (P < 0.05) in administration group, the heavy dose of group of Erding granules has obvious uric acid resisting effect.
experiment conclusion
By research Erding granules in the uric acid resisting effect of mice, rat, Carnis Coturnicis japonicae hyperuricemia pharmacological model, result show that Erding granules has obvious uric acid resisting effect to the mice of hyperuricemia, rat, Carnis Coturnicis japonicae.Can obtain thus, Erding granules has therapeutical effect to hyperuricemia, and simultaneously based on the primary biochemical indicator of hyperuricemia as gout disease, therefore, Erding granules has good preventive effect to gout disease and reduces the serum uric acid effect of gout disease.
In sum, Erding granules has the application in the medicine of preparation treatment or prevention hyperuricemia and gout disease.

Claims (2)

1. Erding granules is treated in preparation or is prevented the application in the medicine of hyperuricemia.
2. Erding granules is treated in preparation or is prevented the application in the medicine of gout disease.
CN201510819922.XA 2015-11-24 2015-11-24 Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases Pending CN105343350A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510819922.XA CN105343350A (en) 2015-11-24 2015-11-24 Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510819922.XA CN105343350A (en) 2015-11-24 2015-11-24 Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases

Publications (1)

Publication Number Publication Date
CN105343350A true CN105343350A (en) 2016-02-24

Family

ID=55319508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510819922.XA Pending CN105343350A (en) 2015-11-24 2015-11-24 Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases

Country Status (1)

Country Link
CN (1) CN105343350A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050201A (en) * 2017-03-09 2017-08-18 吉林修正药业新药开发有限公司 The new application of Chinese patent drug Erding granules
CN109856262A (en) * 2019-01-09 2019-06-07 广西中医药大学 A kind of method that can be used for two fourth preparation main component quantification and qualifications simultaneously
CN111759922A (en) * 2020-08-31 2020-10-13 江西中医药大学 Traditional Chinese medicine composition for treating gout and preparation method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101085254A (en) * 2007-06-26 2007-12-12 北京艺信堂医药研究所 Traditional Chinese medicine for treating uric acid nephritis
CN101474271A (en) * 2008-12-26 2009-07-08 耿顺安 Medicament for treating uarthritis
CN102210787A (en) * 2011-06-10 2011-10-12 中国药科大学 Application of philippine violet herb total phenol extract to treatment of hyperuricemia
CN102362995A (en) * 2011-11-28 2012-02-29 山东中医药大学附属医院 Chinese medicinal preparation for treating acute gouty arthritis, and preparation method thereof
CN102784245A (en) * 2012-08-01 2012-11-21 李虹霖 Erding granule and preparation method thereof
CN104435893A (en) * 2014-12-11 2015-03-25 赵玉 Gout-resisting, inflammation-resisting, blood circulation-promoting and blood stasis-removing and pain-alleviating traditional Chinese medicine composition
CN104873719A (en) * 2015-05-07 2015-09-02 刘海明 Chinese herbal medicine pain-relieving paste

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101085254A (en) * 2007-06-26 2007-12-12 北京艺信堂医药研究所 Traditional Chinese medicine for treating uric acid nephritis
CN101474271A (en) * 2008-12-26 2009-07-08 耿顺安 Medicament for treating uarthritis
CN102210787A (en) * 2011-06-10 2011-10-12 中国药科大学 Application of philippine violet herb total phenol extract to treatment of hyperuricemia
CN102362995A (en) * 2011-11-28 2012-02-29 山东中医药大学附属医院 Chinese medicinal preparation for treating acute gouty arthritis, and preparation method thereof
CN102784245A (en) * 2012-08-01 2012-11-21 李虹霖 Erding granule and preparation method thereof
CN104435893A (en) * 2014-12-11 2015-03-25 赵玉 Gout-resisting, inflammation-resisting, blood circulation-promoting and blood stasis-removing and pain-alleviating traditional Chinese medicine composition
CN104873719A (en) * 2015-05-07 2015-09-02 刘海明 Chinese herbal medicine pain-relieving paste

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王木兰 等,: "二丁颗粒抗痛风药效学研究", 《中药药理与临床》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050201A (en) * 2017-03-09 2017-08-18 吉林修正药业新药开发有限公司 The new application of Chinese patent drug Erding granules
CN109856262A (en) * 2019-01-09 2019-06-07 广西中医药大学 A kind of method that can be used for two fourth preparation main component quantification and qualifications simultaneously
CN109856262B (en) * 2019-01-09 2021-07-30 广西中医药大学 Method for qualitative and quantitative analysis of main components of Erding preparation simultaneously
CN111759922A (en) * 2020-08-31 2020-10-13 江西中医药大学 Traditional Chinese medicine composition for treating gout and preparation method and application thereof
CN111759922B (en) * 2020-08-31 2021-11-26 江西中医药大学 Traditional Chinese medicine composition for treating gout and preparation method and application thereof

Similar Documents

Publication Publication Date Title
CN101933991B (en) Analgesic and anti-inflammatory medicament and preparation method thereof
CN101632827B (en) Traditional Chinese medicine composition for treating psoriasis and preparation method thereof
CN105832794A (en) Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia
CN112716989A (en) Celery seed extract and preparation method and application thereof
CN102920743A (en) Application of spirulina in preparation of anti-hyperuricemia and anti-uarthritis medicine or health-care food
CN101810715B (en) New application of fructus evodiae and extracts and compounds thereof
CN105343350A (en) Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases
CN102716394B (en) Medicine composition for treating skin diseases
CN102225153B (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus and preparation method thereof
CN101926896B (en) Traditional Chinese medicinal preparation for treating gout and preparation method thereof
CN101040891B (en) Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids
CN104804056A (en) Sarcopyramis nepalensis extract and application thereof
CN102940750B (en) Medicine composition for treating gout
CN106420883A (en) Composition with anti-gout effect and preparation method and application thereof
CN102940747B (en) Medicine composition for treating gout
CN102973585B (en) Application of gentiopicroside in treatment of hyperuricemia
CN112439018A (en) Composition with weight-losing and lipid-lowering functions as well as preparation method and application thereof
CN102274428B (en) Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof
CN104435079A (en) Traditional Chinese medicinal composition for treating gout
CN115364179B (en) Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof
CN104510857B (en) A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof
CN102631419B (en) Medicine composition for treating gout, as well as preparation method and application of medicine composition
CN106902330B (en) Traditional Chinese medicine preparation for treating rheumatic arthritis and rheumatalgia and preparation method and application thereof
CN102499913A (en) Preparation method for refined and purified paeonol preparation
CN1569085A (en) Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160224